Health Canada conditionally approved Leqembi (lecanemab) to treat mild cognitive impairment or dementia due to early ...

Michela Luciano is a Science Writer at BioNews. Originally from the picturesque mountain town of L’Aquila, Italy, Michela ...

Alzheimer’s disease is a progressive neurodegenerative disorder and the most common cause of dementia. It most often emerges during a person’s mid-60s or older, although early-onset varieties exist.

There is no cure for Alzheimer’s Disease (AD), but some medications may help reduce the symptoms or slow progression of the disease. As AD progresses, brain cells die and the connections between them ...

A biomarker blood test called AlzoSure Predict that can help to identify people with mild cognitive impairment who are likely progress to Alzheimer’s disease — years before symptoms are evident — has ...

What is Aduhelm for Alzheimer’s? Aduhelm (aducanumab) is an antibody that targets amyloid-beta, the protein that builds up inside nerve cells in those with Alzheimer’s disease. The treatment was ...

There’s still life to live, however, and friends, family, and caregivers are integral to living the best life possible after a diagnosis. A fourth of all Americans 65 and older who live in communities ...

Patients with Alzheimer’s disease (AD) experience a slow progressive decline in memory and cognitive ability, among other symptoms, due to the spread of damage in the brain. Generally, the disease is ...

A single oral dose of methylene blue is able to increase the response of brain regions that control attention and short-term memory, according to University of Texas Health Science Center researchers.

There is a rapid growth in the number of people living with Alzheimer’s disease, and only around one in four people with the disease get diagnosed. It is estimated that there are approximately 44 ...

Alzheimer’s disease affects every aspect of a person’s being, altering personality and behaviors. A loved one diagnosed with dementia may behave irrationally or rudely toward family members, ...

Researchers at Massachusetts General Hospital (MGH) are looking to flip the molecular switch for inflammatory diseases such as Alzheimer’s to the “off” position. Masao Kaneki, MD, PhD, in the ...